About Biosimilars Council
Our Mission
The Biosimilars Council works to increase patient access to lifesaving, affordable biosimilar medicines. Leveraging our deep relationships on Capitol Hill, in federal agencies like FDA and CMS, and in the states, we strive to create a positive regulatory, reimbursement, political and policy environment to assure biosimilars thrive, providing billions in savings to patients and the health care system. Our members include biosimilar manufacturers and stakeholders working to promote biosimilar products in the U.S. market.
The Biosimilars Council is a division of the Association for Accessible Medicines, an organization dedicated to improving access to safe, quality, effective medicine. To learn more, visit www.accessiblemeds.org.
“Biosimilars hold the key to ensuring affordable access to biologic-alternatives medicines for all consumers. We exist to educate, advocate, and promote the development of these products.”
Become a Member
Learn why the Biosimilars Council is the “go-to” source for information about policy, regulatory or legislative issues in the biosimilars industry. When your company invests in Biosimilars Council membership through the Association for Accessible Medicines, we amplify your voice and advocate for your interests.
Our Team
Alex Keeton
Executive Director Biosimilars Council
Alex Keeton is the Executive Director of the Biosimilars Council and leads the policy team at the Association for Accessible Medicines (AAM). A healthcare policy and government affairs leader with extensive experience on issues related to health insurance and prescription drugs, he most recently served as Vice President, Pharmacy Care Services, at UnitedHealth Group, where he shaped enterprise strategy around drug affordability and pharmacy benefits.
Previously, Alex held senior policy roles at the Biotechnology Innovation Organization and America’s Health Insurance Plans, providing research, analysis, and advocacy on complex health policy issues. Alex holds a MPP in Health Policy from The George Washington University and a BA in Communications, Law, Economics, and Government from American University.
Alisha Sud
Director, Policy, Association for Accessible Medicines (AAM)
Alisha Sud is Director of Policy at the Association for Accessible Medicines. Alisha is responsible for collaborating with leadership to identify and respond to key policy issues affecting AAM and Biosimilars Council members. She also manages research initiatives, public comments, policy papers, and other materials that advance the strategic goals and mission of AAM and the Biosimilars Council.
Prior to joining AAM, Alisha was Associate Director of FasterCures, a center of the Milken Institute focused on creating a patient-centered system that accelerates science research, dismantles barriers to access, and connects patients with treatments. Alisha previously worked at global strategic advisory and commercial diplomacy firm Albright Stonebridge Group.
Alisha has extensive experience working with public and private stakeholders to advance global and domestic health policy initiatives. Alisha received her Bachelor of Arts from the University of Vermont with a degree in International Development and a certificate in International Studies from the Johns Hopkins University School of Advanced International Studies. Alisha is currently a Master of Public Health candidate at the Bloomberg School of Public Health.
